Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

2(25%)

Results Posted

100%(5 trials)

Phase Distribution

Ph phase_3

63%

Ph phase_2

25%

Ph phase_1

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

1(12.5%)

Phase 2Efficacy & side effects

2(25.0%)

Phase 3Large-scale testing

5(62.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(5)

Detailed Status

Completed5

Recruiting1

Not yet recruiting1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (12.5%)

Phase 22 (25.0%)

Phase 35 (62.5%)

Trials by Status

recruiting113%

not_yet_recruiting113%

active_not_recruiting113%

completed563%

Recent Activity

2 active trials

Showing 5 of 8

recruitingphase_3

A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose

NCT06866405

not_yet_recruitingphase_3

A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.

NCT07543380

active_not_recruitingphase_3

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.

NCT05035212

completedphase_3

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease

NCT05842967

completedphase_3

A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

NCT04424316

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT06866405Phase 3

A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose

Recruiting

NCT07543380Phase 3

A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.

Not Yet Recruiting

NCT05035212Phase 3

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.

Active Not Recruiting

NCT05842967Phase 3

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease

Completed

NCT04424316Phase 3

A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

Completed

NCT05886777Phase 2

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

Completed

NCT05788237Phase 1

A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults

Completed

NCT04785612Phase 2

Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults

Completed

All 8 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 8